Want to see WVE full AI Analyst Report?
WVE Stock Chart & Stats
$5.25
$0.12(2.07%)
At close: 4:00 PM EDT
$5.25
$0.12(2.07%)
Day’s Range― - ―
52-Week Range$3.04 - $21.73
Previous CloseN/A
Volume649.21K
Average Volume (3M)3.15M
Market Cap
$674.52M
Enterprise Value$738.28M
Total Cash (Recent Filing)$490.60M
Total Debt (Recent Filing)$43.59M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Oct 27, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding197,228,060
10 Day Avg. Volume2,858,662
30 Day Avg. Volume3,153,529
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)5.45
Price to Sales (P/S)67.10
P/FCF Ratio-15.29
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue11.29
Enterprise Value/Gross Profit11.70
Enterprise Value/Ebitda-3.74
Forecast
1Y Price Target
$18.74Price Target Upside256.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-1.13
Revenue Forecast (FY)$50.44M
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline MomentumWave is advancing multiple RNA-based candidates across obesity, alpha-1 antitrypsin deficiency, and liver disease. Progress into mid-stage development, completed dosing cohorts, and planned clinical submissions broaden potential future product opportunities and support platform validation.
RNA Platform DifferentiationThe company’s proprietary chemistry and RNA-targeting design capabilities may provide a durable competitive foundation if they consistently improve potency or dosing durability. Applying the platform across several serious diseases can create additional value from shared scientific and development capabilities.
Liquidity And Low LeverageA substantial cash balance and modest debt provide financial flexibility while Wave advances expensive clinical programs. Runway into Q3 2028 reduces near-term reliance on capital markets and gives management time to reach development milestones, pursue partnerships, and potentially secure additional funding.
Bears Say
Persistent Losses And Cash BurnWave remains structurally unprofitable, with operating losses translating into substantial cash outflows. Continued investment in clinical development may sustain this burden for several quarters, increasing dependence on existing reserves, collaboration receipts, milestone payments, or future financing.
Declining Collaboration RevenueThe sharp decline in collaboration revenue highlights the variability of Wave’s current funding model and its dependence on partner-related receipts. With no established marketed-product revenue described, uneven collaborations can make operating resources and financial performance less predictable.
Clinical And Regulatory UncertaintyKey value drivers still depend on clinical readouts, regulatory requirements, and partnership outcomes that are not yet resolved. Delays, additional study demands, or a changed DMD strategy could extend development timelines and postpone potential product revenue or milestone realization.
Wave Life Sciences News
WVE FAQ
What was Wave Life Sciences’s price range in the past 12 months?
Wave Life Sciences lowest stock price was $3.04 and its highest was $21.73 in the past 12 months.
What is Wave Life Sciences’s market cap?
Wave Life Sciences’s market cap is $674.52M.
When is Wave Life Sciences’s upcoming earnings report date?
Wave Life Sciences’s upcoming earnings report date is Oct 27, 2026 which is in 4 days.
How were Wave Life Sciences’s earnings last quarter?
Wave Life Sciences released its earnings results on Jul 30, 2026. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.3 by -$0.04.
Is Wave Life Sciences overvalued?
According to Wall Street analysts Wave Life Sciences’s price is currently Undervalued.
Does Wave Life Sciences pay dividends?
Wave Life Sciences does not currently pay dividends.
What is Wave Life Sciences’s EPS estimate?
Wave Life Sciences’s EPS estimate is -0.33.
How many shares outstanding does Wave Life Sciences have?
Wave Life Sciences has 197,228,060 shares outstanding.
What happened to Wave Life Sciences’s price movement after its last earnings report?
Wave Life Sciences reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.3. Following the earnings report the stock price went down -0.861%.
Which hedge fund is a major shareholder of Wave Life Sciences?
Currently, no hedge funds are holding shares in WVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wave Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.74 (256.97% Upside)
$18.74 (256.97% Upside)
Blogger Sentiment
Neutral
WVE Sentiment 56%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 672.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.07%
12-Months-Change
Fundamentals
Return on Equity
-50.12%
Trailing 12-Months
Asset Growth
121.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
WVE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial clinical momentum across the lead programs (WVE-007, WVE-006, WVE-008) with compelling early human and preclinical data, regulatory engagement (FDA meeting for 006), and a solid cash balance supporting operations into Q3 2028. Offsetting these positives are a pronounced YoY revenue decline (-73.6%), rising R&D and G&A spend driving a larger net loss (+37.4% YoY), dependency on future milestone payments not included in runway calculations, and timing/regulatory uncertainties (including partnership-driven strategy for DMD). On balance, the clinical and platform progress and runway position are dominant positives despite near-term financial headwinds and program/timing uncertainties.View all WVE earnings summariesWVE Stock 12 Month Forecast
Average Price Target
$18.74
▲(256.97% Upside)
Technical Analysis
Arbutus Biopharma
―
Arcturus Therapeutics
―
Benitec Biopharma
―
Editas Medicine
―
Silence Therapeutics
―
Ownership Overview
28.50% Insiders
14.23% Mutual Funds
0.02% Other Institutional Investors
48.20% Public Companies and
Individual Investors